Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Duchenne muscular dystrophy
Dongsheng Duan, Nathalie Goemans, Shin’ichi Takeda, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 830

Showing 1-25 of 830 citing articles:

Single-nucleus cross-tissue molecular reference maps toward understanding disease gene function
Gökçen Eraslan, Eugene Drokhlyansky, Shankara Anand, et al.
Science (2022) Vol. 376, Iss. 6594
Open Access | Times Cited: 280
Casimersen: First Approval
Matt Shirley
Drugs (2021) Vol. 81, Iss. 7, pp. 875-879
Closed Access | Times Cited: 211
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Jiang-Hui Wang, Dominic J. Gessler, Wei Zhan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 196
Applications of multi‐omics analysis in human diseases
Chongyang Chen, Jing Wang, Donghui Pan, et al.
MedComm (2023) Vol. 4, Iss. 4
Open Access | Times Cited: 182
Gene Therapy for Duchenne Muscular Dystrophy
Nertiyan Elangkovan, George Dickson
Journal of Neuromuscular Diseases (2021) Vol. 8, Iss. s2, pp. S303-S316
Open Access | Times Cited: 148
Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular Dystrophy
Angela Lek, Brenda Wong, Allison M. Keeler, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 13, pp. 1203-1210
Open Access | Times Cited: 141
Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models
Chady H. Hakim, Sandeep Kumar, Dennis O. Pérez‐López, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 118
Oligonucleotide Therapeutics: From Discovery and Development to Patentability
Lara Moumné, Anne-Céline Marie, Nicolas Crouvezier
Pharmaceutics (2022) Vol. 14, Iss. 2, pp. 260-260
Open Access | Times Cited: 105
Delandistrogene Moxeparvovec: First Approval
Sheridan M. Hoy
Drugs (2023) Vol. 83, Iss. 14, pp. 1323-1329
Closed Access | Times Cited: 93
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
Marlen C. Lauffer, Willeke M. C. van Roon‐Mom, Annemieke Aartsma‐Rus
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 82
Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases
Qian Lu, Yanli Zhu, Chao Deng, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 81
Inflammation balance in skeletal muscle damage and repair
Huiyin Tu, Yu‐Long Li
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 72
Duchenne muscular dystrophy: disease mechanism and therapeutic strategies
Addeli Bez Batti Angulski, Nora Hosny, Houda Cohen, et al.
Frontiers in Physiology (2023) Vol. 14
Open Access | Times Cited: 71
Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects
Qin Ru, Yusheng Li, Lin Chen, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 60
RNA‐based medicine: from molecular mechanisms to therapy
Anke Sparmann, Jörg Vogel
The EMBO Journal (2023) Vol. 42, Iss. 21
Open Access | Times Cited: 58
Chemically Modified Platforms for Better RNA Therapeutics
Yesi Shi, Xueyan Zhen, Yiming Zhang, et al.
Chemical Reviews (2024) Vol. 124, Iss. 3, pp. 929-1033
Closed Access | Times Cited: 51
Lethal immunotoxicity in high-dose systemic AAV therapy
Dongsheng Duan
Molecular Therapy (2023) Vol. 31, Iss. 11, pp. 3123-3126
Open Access | Times Cited: 49
Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy
Sharla M. Birch, Michael W. Lawlor, Thomas J. Conlon, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 677
Closed Access | Times Cited: 46
Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach
Grant Patterson, Haley Conner, Mecham Groneman, et al.
European Journal of Pharmacology (2023) Vol. 947, pp. 175675-175675
Closed Access | Times Cited: 43
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Eugenio Mercuri, Juan J. Vílchez, Odile Boespflug‐Tanguy, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 4, pp. 393-403
Closed Access | Times Cited: 43
Synthesis and clinical application of new drugs approved by FDA in 2023
Yatao Wang, Pengcheng Yang, Yanfeng Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116124-116124
Closed Access | Times Cited: 20
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
Jerry R. Mendell, Francesco Muntoni, Craig M. McDonald, et al.
Nature Medicine (2024)
Open Access | Times Cited: 20
Hearts apart: sex differences in cardiac remodeling in health and disease
Thomas G. Martin, Leslie A. Leinwand
Journal of Clinical Investigation (2024) Vol. 134, Iss. 13
Open Access | Times Cited: 18
Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles
Francesco Millozzi, Paula Milán-Rois, Arghya Sett, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 5
Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy
Rachael A. Potter, Ida Moeller, Sohrab Khan, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top